Engineered immune cells for advanced sarcoma
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR T cells) for people with advanced or recurrent sarcoma, a type of cancer that starts in bones or soft tissues. The treatment aims to help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sarcoma that is stage III or IV, or has come back after treatment.
- You are between 18 and 65 years old.
- You have finished chemotherapy or radiation at least 4 weeks ago, and stopped taking immune-suppressing drugs (like steroids) at least 1 week ago.
- Your cancer cells have a specific marker (antigen) that the treatment targets, confirmed by a lab test.
- You are generally well enough to care for yourself (Karnofsky score of 50% or higher).
- Your blood counts, liver, and kidney function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, modified to attack sarcoma cancer cells. It may help people with advanced or recurrent sarcoma who have not responded to other treatments.
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.